Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

2018 ◽  
Vol 25 (2) ◽  
pp. 181-191 ◽  
Author(s):  
Radica Z. Alicic ◽  
Emily J. Johnson ◽  
Katherine R. Tuttle
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Diabetic Kidney ◽  
New Biomarkers

scholarly journals MicroRNAs: new biomarkers and promising therapeutic targets for diabetic kidney disease

2019 ◽  
Vol 41 (3) ◽  
pp. 412-422 ◽  
Author(s):  
Linicene Rosa do Nascimento ◽  
Caroline Pereira Domingueti
Keyword(s):  
Kidney Disease ◽  
Messenger Rna ◽  
Diabetic Kidney Disease ◽  
Regulation Of Gene Expression ◽  
Therapeutic Targets ◽  
Diabetic Kidney ◽  
Rna Molecules ◽  
Global Health Issue ◽  
New Biomarkers ◽  
Post Transcriptional Regulation

Abstract Diabetic kidney disease (DKD) is a chronic complication of diabetes mellitus associated with significant morbidity and mortality regarded as a global health issue. MicroRNAs - small RNA molecules responsible for the post-transcriptional regulation of gene expression by degradation of messenger RNA or translational repression of protein synthesis - rank among the factors linked to the development and progression of DKD. This study aimed to offer a narrative review on investigations around the use of microRNAs in the diagnosis, monitoring, and treatment of DKD. Various microRNAs are involved in the pathogenesis of DKD, while others have a role in nephroprotection and thus serve as promising therapeutic targets for DKD. Serum and urine microRNAs levels have also been considered in the early diagnosis and monitoring of individuals with DKD, since increases in albuminuria, decreases in the glomerular filtration rate, and progression of DKD have been linked to changes in the levels of some microRNAs.

scholarly journals Cohort profile: the Singapore diabetic cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e036443 ◽  
Author(s):  
Miyang Luo ◽  
Linda Wei Lin Tan ◽  
Xueling Sim ◽  
Milly Khiam Hoon Ng ◽  
Rob Van Dam ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Sample Collection ◽  
Data Set ◽  
Diabetic Kidney ◽  
New Biomarkers ◽  
Rich Data

PurposeThe diabetic cohort (DC) was set up to study the determinants of complications in individuals with type 2 diabetes and examine the role of genetic, physiological and lifestyle factors in the development of complications in these individuals.ParticipantsA total of 14 033 adult participants with type 2 diabetes were recruited from multiple public sector polyclinics and hospital outpatient clinics in Singapore between November 2004 and November 2010. The first round of follow-up was conducted for 4131 participants between 2012 and 2016; the second round of follow-up started in 2016 and is expected to end in 2021. A questionnaire survey, physical assessments, blood and urine sample collection were conducted at recruitment and each follow-up visit. The data set also includes genetic data and linkage to medical and administrative records for recruited participants.Findings to dateData from the cohort have been used to identify determinants of diabetes and related complications. The longitudinal data of medical records have been used to analyse diabetes control over time and its related outcomes. The cohort has also contributed to the identification of genetic loci associated with type 2 diabetes and diabetic kidney disease in collaboration with other large cohort studies. About 25 scientific papers based on the DC data have been published up to May 2019.Future plansThe rich data in DC can be used for various types of research to study disease-related complications in patients with type 2 diabetes. We plan to further investigate disease progression and new biomarkers for common diabetic complications, including diabetic kidney disease and diabetic neuropathy.

scholarly journals Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease

2020 ◽  
Vol 21 (11) ◽  
pp. 4113
Author(s):  
Julio M. Martinez-Moreno ◽  
Miguel Fontecha-Barriuso ◽  
Diego Martin-Sanchez ◽  
Juan Guerrero-Mauvecin ◽  
Elena Goma-Garces ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Epigenetic Regulation ◽  
Diabetic Kidney Disease ◽  
Molecular Mechanisms ◽  
Therapeutic Targets ◽  
Sglt2 Inhibitors ◽  
Post Translational Modifications ◽  
Diabetic Kidney ◽  
Bet Inhibitor

Diabetic kidney disease is one of the fastest growing causes of death worldwide. Epigenetic regulators control gene expression and are potential therapeutic targets. There is functional interventional evidence for a role of DNA methylation and the histone post-translational modifications—histone methylation, acetylation and crotonylation—in the pathogenesis of kidney disease, including diabetic kidney disease. Readers of epigenetic marks, such as bromodomain and extra terminal (BET) proteins, are also therapeutic targets. Thus, the BD2 selective BET inhibitor apabetalone was the first epigenetic regulator to undergo phase-3 clinical trials in diabetic kidney disease with an endpoint of kidney function. The direct therapeutic modulation of epigenetic features is possible through pharmacological modulators of the specific enzymes involved and through the therapeutic use of the required substrates. Of further interest is the characterization of potential indirect effects of nephroprotective drugs on epigenetic regulation. Thus, SGLT2 inhibitors increase the circulating and tissue levels of β-hydroxybutyrate, a molecule that generates a specific histone modification, β-hydroxybutyrylation, which has been associated with the beneficial health effects of fasting. To what extent this impact on epigenetic regulation may underlie or contribute to the so-far unclear molecular mechanisms of cardio- and nephroprotection offered by SGLT2 inhibitors merits further in-depth studies.

scholarly journals Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
Stephanie Toth-Manikowski ◽  
Mohamed G. Atta
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Renin Angiotensin System ◽  
Current Understanding ◽  
Angiotensin System ◽  
Diabetic Kidney ◽  
Alternative Pathways ◽  
The Past ◽  
The Way

Diabetes is a worldwide epidemic that has led to a rise in diabetic kidney disease (DKD). Over the past two decades, there has been significant clarification of the various pathways implicated in the pathogenesis of DKD. Nonetheless, very little has changed in the way clinicians manage patients with this disorder. Indeed, treatment is primarily centered on controlling hyperglycemia and hypertension and inhibiting the renin-angiotensin system. The purpose of this review is to describe the current understanding of how the hemodynamic, metabolic, inflammatory, and alternative pathways are all entangled in pathogenesis of DKD and detail the various therapeutic targets that may one day play a role in quelling this epidemic.

scholarly journals New Insights into Diabetic Kidney Disease: The Potential Pathogenesis and Therapeutic Targets

2017 ◽  
Vol 2017 ◽  
pp. 1-2 ◽  
Author(s):  
Wei Jing Liu ◽  
Jochen Reiser ◽  
Tae Sun Park ◽  
Zhangsuo Liu ◽  
Shuta Ishibe
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Diabetic Kidney
Sign in / Sign up

Export Citation Format

Share Document